Biovie is trading 5.21% down at $2.00, with no verified company-specific announcement identified on August 27, 2026, and the catalyst remains unclear.
- Its latest major update remains the August 6 Parkinson’s trial announcement; filings include an August 14 S-1/A and an August 13 annual report highlighting financing and going-concern risks.
- Broader markets are higher and do not clearly explain the decline; the move may reflect profit-taking or continued volatility after Biovie’s sharp August 19–20 advance.